Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05447897 · ClinicalTrials.gov registry record · NA

Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers

A NA study of Smoking Cessation, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
9
Enrollment target
1
Study location

NCT05447897: Completed NA study of Smoking Cessation, sponsored by University of Colorado, Denver.

NCT05447897 is a NA study of Smoking Cessation that has completed, run by University of Colorado, Denver. The registered enrollment target is 9 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05447897, a NA study of Smoking Cessation, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

Tobacco use is the leading preventable cause of death in the US and a major driver of health disparities. Among our tools for reducing the harms of tobacco is lung cancer screening (LCS). This study will combine a review of existing qualitative and quantitative data on barriers to lung cancer screening and smoking cessation in underserved populations, a quantitative analysis of predictors of lung cancer screening and smoking cessation treatment use among Massachusetts Federally Qualified Health Centers (FQHC)s, and a stakeholder advisory group to synthesize these data and select implementation strategies that reflects the critical determinants and the strengths and resource constraints of the Federally Qualified Health Centers (FQHC) context.

Primary Outcome

Feasibility of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes

Conditions Studied

Interventions

  • OTHER Qualitative Group Interviews
  • OTHER Stakeholder advisory group

Study Locations (1)

Massachusetts

  • Massacusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2022-12-01
Est. Completion 2023-05-31
Phase NA
University of Colorado, Denver

1,283 total trials

What the finished NCT05447897 record still lists

NCT05447897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Qualitative Group Interviews is the first listed.

NCT05447897 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05447897 about?

NCT05447897 is a clinical study titled "Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers". Tobacco use is the leading preventable cause of death in the US and a major driver of health disparities. Among our tools for reducing the harms of tobacco is lung cancer screening (LCS). This study will combine a review of existing qualitative and quantitative data on barriers to lung cancer screen...

What is the current status of trial NCT05447897?

This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2022-12-01. Estimated completion is 2023-05-31.

What conditions does trial NCT05447897 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT05447897?

The interventions under investigation include: Qualitative Group Interviews (OTHER), Stakeholder advisory group (OTHER).

Who is sponsoring clinical trial NCT05447897?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05447897 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05447897's enrollment target sits among peer trials

9 187th of 188 higher than 2 of 188 other Smoking Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05447897, the US trial registry maintained by the National Library of Medicine. NCT05447897 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.